

## **APPLICATION DATA SHEET**

### **Application Information**

Title Line One ::	Naphthalamide Compositions and Uses Thereof
Title Line Two ::	
Title Line Three ::	
Total Drawing Sheets ::	3
Formal Drawings ::	
Application Type :	Utility
Docket Number ::	A-70245-2/RFT/THR
Licensed - U S Government Agency ::	
Contract Number ::	
Grant Number ::	
Secrecy Order in Parent Application ::	
Request for Early Publication?::	
Request for Non-Publication?::	
Small Entity::	Yes

### **Inventor Information**

Inventor One Given Name ::	Dennis M.
Family Name ::	Brown
Name Suffix ::	
Postal Address Line One ::	100 San Mateo Drive
Postal Address Line Two ::	
City ::	Menlo Park
State or Province ::	CA
Country ::	USA
Postal or Zip Code ::	94025
City of Residence ::	Menlo Park
State or Prov. of Residence ::	CA
Country of Residence ::	USA
Citizenship Country ::	US

Inventor Two Given Name ::	
Family Name ::	
Name Suffix ::	
Postal Address Line One ::	
Postal Address Line Two ::	
City ::	
State or Province ::	
Country ::	
Postal or Zip Code ::	
City of Residence ::	
State or Prov. of Residence ::	
Country of Residence ::	
Citizenship Country ::	

### **Correspondence Information**

Name Line One :: Richard F. Trecartin  
Address Line One :: Dorsey & Whitney LLP  
Address Line Two :: Intellectual Property Department  
Address Line Three :: Four Embarcadero Center, Suite 3400  
City :: San Francisco  
State or Province :: CA  
Postal or Zip Code :: 94111-4187  
Telephone :: 415-781-1989  
Fax :: 415-398-3249  
E-Mail ::

### **Representative Information**

Representative Customer Number :: **32940**

### **Domestic Priority Information**

<b>Application::</b>	<b>Continuity Type::</b>	<b>Parent Application::</b>	<b>Parent Filing Date::</b>
This Application	Divisional	09/834,177	April 12, 2001
09/834,177	Non-Provisional	60/197,103	April 12, 2000
This Application	Continuation-in-Part	09/810,527	March 15, 2001

### **Prior Foreign Applications**

Country:: Application Number:: Filing Date::

### **Assignee Information**

Assignee Name:: ChemGenex Therapeutics, Inc.